Pulmonary arterial hypertension (PAH) is a complex and progressive condition characterized by elevated blood pressure in the pulmonary arteries, leading to serious health complications and reduced quality of life. It can result from various underlying causes, including genetic factors, connective tissue diseases, and chronic lung conditions. Effective management of PAH is crucial, as it can significantly impact patients' daily activities and overall prognosis. In recent years, advancements in medical research have led to a variety of treatment options, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. These therapies aim to improve symptoms, enhance exercise capacity, and slow disease progression. This introduction will provide an overview of the available medications for PAH, their mechanisms of action, and their role in helping patients manage this challenging condition.
|
|
|
|
